tiprankstipranks
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Holding ALDX?
Track your performance easily

Aldeyra Therapeutics (ALDX) Income Statement

1,535 Followers

Aldeyra Therapeutics Income Statement

Last quarter (Q ), Aldeyra Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Aldeyra Therapeutics's net income was $-15.11M. See Aldeyra Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 49.64M$ 42.79M$ 62.68M$ 56.22M$ 32.91M$ 63.07M
Operating Income
$ -49.64M$ -42.79M$ -62.68M$ -56.22M$ -36.42M$ -63.07M
Net Non Operating Interest Income Expense
$ 5.32M$ 5.25M$ 655.35K$ -1.56M$ -1.61M$ 937.50K
Other Income Expense
$ -100.00K$ -100.00K----
Pretax Income
$ -44.32M$ -37.54M$ -62.02M$ -57.78M$ -38.03M$ -62.14M
Tax Provision
----$ -479.26K$ -1.31M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -44.80M$ -37.54M$ -62.02M$ -57.78M$ -37.55M$ -60.83M
Basic EPS
$ -0.75$ -0.64$ -1.06$ -1.07$ -1.11-
Diluted EPS
$ -0.75$ -0.64$ -1.06$ -1.07$ -1.11$ -2.24
Basic Average Shares
$ 236.16M$ 58.59M$ 58.41M$ 54.04M$ 33.97M$ 27.11M
Diluted Average Shares
$ 236.16M$ 58.59M$ 58.41M$ 54.04M$ 33.97M$ 27.15M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 49.64M$ 42.79M$ 62.68M$ 56.22M$ 32.91M$ 63.07M
Net Income From Continuing And Discontinued Operation
$ -44.80M$ -37.54M$ -62.02M$ -57.78M$ -37.55M$ -60.83M
Normalized Income
$ -34.92M$ -29.66M----
Interest Expense
------
EBIT
$ -43.31M$ -35.47M$ -60.33M$ -56.03M$ -36.13M$ -61.53M
EBITDA
$ -42.81M$ -35.21M$ -60.07M$ -55.77M$ -36.07M$ -61.77M
Currency in USD

Aldeyra Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis